David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Thursday, June 18, 2015

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate endpoint.

April 2019, Volume 5, Issue 5

Focus on Lymphoid Malignancies (Volume 5, Issue 4.1)

March 2019, Volume 5, Issue 4

February 2019, Volume 5, Issue 3

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Recent Articles

CMML: A Unique Overlap Syndrome Receiving Increased Attention

New Treatment Options Lead to New Questions in Acute Myeloid Leukemia

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Current Issue

April 2019, Volume 5, Issue 5

Meeting Coverage

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Editor`s Corner

The Day I Was Schooled on CME

The Color of Blood and “Exohematology”